AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

 10,700.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 13,276.00
  • 52 Week Low: 9,667.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.64m
  • Volume: 0
  • Market Cap: £165,918m
  • RiskGrade: 123

Latest ShareCast News

AstraZeneca's Calquence gets Europe approval for MCL

By Josh White

Date: Tuesday 06 May 2025

(Sharecast News) - AstraZeneca announced on Tuesday that it has secured European Commission approval for 'Calquence', or acalabrutinib, in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous stem cell transplant.

AstraZeneca ShareCast News

AstraZeneca's Breztri meets all primary endpoint... 02-May-2025 ShareCast
AstraZeneca reports strong first quarter 29-Apr-2025 ShareCast
AstraZeneca receives positive Phase III trial re... 22-Apr-2025 ShareCast
London close: Stocks fall as China retaliates to... 09-Apr-2025 ShareCast
AstraZeneca's Enhertu gets further EU approval 04-Apr-2025 ShareCast

AstraZeneca Regulatory News

Enhertu improved pCR in early-stage breast cancer 07-May-2025 07:30 RNS
Calquence combination approved in EU for 1L MCL 06-May-2025 07:00 RNS
Breztri met primary endpoints in Ph3 asthma trials 02-May-2025 07:00 RNS
Director/PDMR Shareholding 01-May-2025 16:00 RNS
Total Voting Rights 01-May-2025 15:00 RNS

AstraZeneca Newspaper Links

UK’s biggest drug company AstraZeneca plans US e... 29-Apr-2025 Times
Fighting Frenchman shows us how as he ensures As... 30-Dec-2014 Daily Mail
Exclusive: UK firms vie for share of £170bn in A... 08-Dec-2014 The Independent
MARKET REPORT: Ariad on the up amid growing spec... 04-Dec-2014 Daily Mail
Some reasons why Pfizer won’t bid for AstraZenec... 19-Nov-2014 Guardian

AstraZeneca Tips & Analysis

Questor :AstraZeneca 29-Apr-2014 Telegraph
Questor : AstraZeneca 24-Jan-2014 Telegraph
Questor:AstraZeneca 22-Dec-2011 Telegraph
Investment Column:AstraZeneca 28-Oct-2011 The Independent
Investment Column: AstraZeneca 23-Jun-2011 The Independent

AstraZeneca News Wires

MedImmune Announces Zook as President 13-Nov-2008 PR Newswire
Survey Shows Lung Cancer Patients Blamed for The... 12-Nov-2008 PR Newswire
CRESTOR Demonstrates Dramatic CV Risk Reduction ... 09-Nov-2008 PR Newswire

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 10,700.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 13,276.00
52 Week Low 9,667.00
Volume 0
Shares Issued 1,550.64m
Market Cap £165,918m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
94.63% below the market average94.63% below the market average94.63% below the market average94.63% below the market average94.63% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Price Trend
6.92% above the market average6.92% above the market average6.92% above the market average6.92% above the market average6.92% above the market average
50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average
Income
65.76% below the market average65.76% below the market average65.76% below the market average65.76% below the market average65.76% below the market average
14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average
Growth
85.76% above the market average85.76% above the market average85.76% above the market average85.76% above the market average85.76% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average

What The Brokers Say

Strong Buy 10
Buy 14
Neutral 5
Sell 0
Strong Sell 0
Total 29
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 20-Feb-25 08-Aug-24
Paid 24-Mar-25 09-Sep-24
Amount 210.00¢ 100.00¢

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page